TIDMAVO

RNS Number : 6440M

Advanced Oncotherapy PLC

01 August 2017

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company, purchased 100,000 ordinary shares of 25 pence in the Company ("Ordinary Shares") at a price of 17.75 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 1,223,946 Ordinary Shares, representing 1.51% of the Company's issued share capital.

For further information, please contact:

 
 Advanced Oncotherapy                    www.avoplc.com 
  Plc 
 Dr. Michael Sinclair,            Tel: +44 20 3617 8728 
  Executive Chairman 
 Nicolas Serandour, CEO 
 
 Stockdale Securities 
  (Nomad & Joint Broker) 
 Antonio Bossi / David            Tel: +44 20 7601 6100 
  Coaten 
 
 Stifel Nicolaus Europe 
  (Joint Broker) 
 Jonathan Senior / Ben            Tel: +44 20 7710 7600 
  Maddison 
 
 Walbrook PR (Financial        Tel: +44 20 7933 8780 or 
  PR & IR)                           avo@walbrookpr.com 
 Paul McManus / Anna       Mob: +44 7980 541 893 / Mob: 
  Dunphy                               +44 7876 741 001

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBUGDRSSXBGRB

(END) Dow Jones Newswires

August 01, 2017 02:02 ET (06:02 GMT)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Advanced Oncotherapy Charts.
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Advanced Oncotherapy Charts.